SEOM clinical guidelines for the treatment of head and neck cancer (2017)

• L. C. Iglesias Docampo ^[1] ; V. Arrazubi Arrula ^[2] ; N. Baste Rotllan ^[9] ; A. Carral Maseda ^[3] ; B. Cirauqui Cirauqui ^[4] ; Y. Escobar ^[5] ; J. J. Lambea Sorrosal ^[6] ; M. Pastor Borgoñón ^[10] ; A. Rueda ^[7] ; J. J. Cruz Hernández ^[8]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Hospital Universitario de Basurto

     Hospital Universitario de Basurto

     Bilbao, España

     
  3. [3] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  4. [4] Hospital Universitari Germans Trias i Pujol

     Hospital Universitari Germans Trias i Pujol

     Barcelona, España

     
  5. [5] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  6. [6] Hospital Clínico Universitario Lozano Blesa

     Hospital Clínico Universitario Lozano Blesa

     Zaragoza, España

     
  7. [7] Hospital Costa Del Sol

     Hospital Costa Del Sol

     Marbella, España

     
  8. [8] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  9. [9] Hospital Universitario Vall d´Hebrón, España
  10. [10] Hospital Universitari I Politècnic la Fe, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 1 (January 2018), 2018, págs. 75-83
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2013 publication, Spanish Society of Medical Oncology (SEOM) presents an update of HNC diagnosis and treatment guideline. The eighth edition of TNM classification, published in January 2017, introduces important changes for p16-positive oropharyngeal tumours, for lip and oral cavity cancer and for N3 category. In addition, there are new data about induction chemotherapy and the role of immunotherapy in HNC.